Royal Bank of Canada
EW icon

Royal Bank of Canada’s Edwards Lifesciences EW Stock Holding History

Royal Bank of Canada’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-300,000
Closed -$3.29M – 5961
2013
Q4 		$3.29M Hold
300,000
– – ﹤0.01% 1942
2013
Q3 		$3.48M Hold
300,000
– – ﹤0.01% 1810
2013
Q2 		$3.36M Buy
+300,000
New +$3.55M ﹤0.01% 1721

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Royal Bank of Canada's EW Position: Q2 2026 in Review

Royal Bank of Canada increased its Edwards Lifesciences (EW) stake by 43% in Q2 2026, buying an estimated $88.3M and bringing the position to 3,501,447 shares worth $317M. The position accounts for 0.05% of the portfolio, ranked #333.

Royal Bank of Canada first reported a position in EW in Q2 2013 and has held it in 53 quarters since. The position peaked at $842M in Q4 2021. 1,338 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Royal Bank of Canada held 3,501,447 shares of Edwards Lifesciences worth $317M as of Q2 2026.
  • Royal Bank of Canada bought 1,054,448 Edwards Lifesciences shares in Q2 2026, an estimated $88.3M.
  • Edwards Lifesciences made up 0.05% of Royal Bank of Canada's portfolio in Q2 2026, its #333 holding.
  • Royal Bank of Canada first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 53 quarters since.
  • Royal Bank of Canada's Edwards Lifesciences position peaked at $842M in Q4 2021.
  • 1,338 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.